

TRASTUZUMAB PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)			Provider Information (required)			
Date:			Provider Name:			
Patient Name:		Specialty:	N	NPI:		
Date of Birth:	Sex: □Male	□Female	Office Phone:	(Office Fax:	
Street Address:			Office Street Address:			
City:	State:	Zip:	City:	Stat	te:	Zip:
Patient ID: R			Physician Signature:			<u>.I.</u>
IX I	P	HYSICIA	N COMPLETES			
	NOTE: Form m	nust be comp	leted in its entirety for p	processing		
				<u>-</u>		
Please select medication:	<u> </u>	• • • •				
□ Kanjinti (trastuzumab-anns) □ Ogivri (trastuzumab-dkst) □ Ontruzant (trastuzumab-dttb)						mab-dttb)
**Check www.fepblue.org/formulary	to confirm which medic	cation is part of	the patient's benefit			
Is this request for brand or generic? □Brand □Generic						
1. What is the patient's diagnos	is?					
∴ What is the patient's diagnos □HER2 overexpressing breather		□HER2 ov	verexpressing metastatic	gastric adenoc	carcinoma	OR
☐HER2 overexpressing me			1 0	· ·		
	•		for the last 6 months ex		les? □Yes	□No*
•	2 protein overexpres	•	-2 gene amplification be			ipproved
☐Metastatic colorectal cand	er <u>OR</u> Unresed	ctable colored	ctal cancer			
a. Has the patient been on this medication continuously for the last 6 months excluding samples? □Yes □No*						□No*
*If NO, please ans	wer the following q	uestions:				
	nt have RAS wild-ty ☐Yes ☐No	pe unresecta	able or metastatic colorec	ctal cancer, as	determined b	y an FDA-
ii. Is the patient'	s cancer HER2-posi	tive? □Yes	□No			
iii. Has the cancer chemotherapy		ng treatment	with fluoropyrimidine-,	oxaliplatin-, a	and irinotecar	ı-based
b. Will the requested m	edication be used in	combination	n with tucatinib (Tukysa))? □Yes □	lNo	
☐Other (please specify):						
2. Does the prescriber agree to	monitor the patient f	or cardiac fu	nction and pulmonary to	oxicity? □Yes	s 🗖 No	
3. FEMALE Patient : Is the patient be months after the last dose?	advised to use effect	-		with the reques	sted medicati	on and for 7



TRASTUZUMAB PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

faster...
easier...
better...

CVS/caremark

Introducing ePA! Online Prior
Authorizations in minutes through
Caremark.com/ePA. Sign up today!